Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H21N3.ClH |
| Molecular Weight | 339.862 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC1=CC(=CC=C1)N(C)C(=N)NC2=C3C=CC=CC3=CC=C2
InChI
InChIKey=CKAKVKWRMCAYJD-UHFFFAOYSA-N
InChI=1S/C20H21N3.ClH/c1-3-15-8-6-11-17(14-15)23(2)20(21)22-19-13-7-10-16-9-4-5-12-18(16)19;/h4-14H,3H2,1-2H3,(H2,21,22);1H
| Molecular Formula | C20H21N3 |
| Molecular Weight | 303.4008 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Aptiganel (CNS 1102, Cerestat), a selective ligand with antagonized properties for the ion-channel site of the N-methyl-D-aspartate receptor-channel complex, was developed as a neuroprotective agent for focal brain ischemia. However, in the clinical trials in patients with acute ischemic stroke aptiganel was not efficacious at either of the tested doses and may be harmful. That is why its further study was discontinued.
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Catalpol increases brain angiogenesis and up-regulates VEGF and EPO in the rat after permanent middle cerebral artery occlusion. | 2010-08-20 |
|
| Caffeinol at the receptor level: anti-ischemic effect of N-methyl-D-aspartate receptor blockade is potentiated by caffeine. | 2010-02 |
|
| The rise and fall of NMDA antagonists for ischemic stroke. | 2004-03 |
|
| Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors. | 2003-12 |
|
| Excitatory amino acid antagonists for acute stroke. | 2003 |
|
| Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? | 2002-10 |
|
| Patient safety in trials of therapy for acute ischemic stroke. | 2002-02-27 |
|
| Future of neuroprotective drugs in doubt. | 2002-01 |
|
| Glutamate AMPA receptor antagonist treatment for ischaemic stroke. | 2002 |
|
| Ensuring patient safety in clinical trials for treatment of acute stroke. | 2001-12-05 |
|
| Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. | 2001-12-05 |
|
| Effects of cerestat and NBQX on functional and morphological outcomes in rat focal cerebral ischemia. | 2001-03 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9260729
Short intravenous infusions of up to 30 microg/kg have been well tolerated by healthy male volunteers. There were undertook a randomized, double-blind, placebo-controlled study in 20 male volunteers to examine the safety, tolerability, and cardiovascular and psychomotor effects of a dosing paradigm similar to that envisaged for therapeutic use. Aptiganel HCl was infused over 4 h in total doses of 15, 32, 50, or 73 microg kg.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8295213
N-1-naphthyl-N'-(3-ethylphenyl)-N'-methylguanidine (aptiganel) showed high affinity for the NMDA receptor ion channel site (IC50 = 36 nM vs [3H]-3) and low affinity for sigma receptors (IC50 = 2540 nM vs [3H]-5)
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:05:43 GMT 2025
by
admin
on
Mon Mar 31 18:05:43 GMT 2025
|
| Record UNII |
40PWH14OXW
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1509
Created by
admin on Mon Mar 31 18:05:43 GMT 2025 , Edited by admin on Mon Mar 31 18:05:43 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID9045762
Created by
admin on Mon Mar 31 18:05:43 GMT 2025 , Edited by admin on Mon Mar 31 18:05:43 GMT 2025
|
PRIMARY | |||
|
GG-9
Created by
admin on Mon Mar 31 18:05:43 GMT 2025 , Edited by admin on Mon Mar 31 18:05:43 GMT 2025
|
PRIMARY | |||
|
CHEMBL92484
Created by
admin on Mon Mar 31 18:05:43 GMT 2025 , Edited by admin on Mon Mar 31 18:05:43 GMT 2025
|
PRIMARY | |||
|
137160-11-3
Created by
admin on Mon Mar 31 18:05:43 GMT 2025 , Edited by admin on Mon Mar 31 18:05:43 GMT 2025
|
PRIMARY | |||
|
40PWH14OXW
Created by
admin on Mon Mar 31 18:05:43 GMT 2025 , Edited by admin on Mon Mar 31 18:05:43 GMT 2025
|
PRIMARY | |||
|
300000055067
Created by
admin on Mon Mar 31 18:05:43 GMT 2025 , Edited by admin on Mon Mar 31 18:05:43 GMT 2025
|
PRIMARY | |||
|
m2017
Created by
admin on Mon Mar 31 18:05:43 GMT 2025 , Edited by admin on Mon Mar 31 18:05:43 GMT 2025
|
PRIMARY | Merck Index | ||
|
60839
Created by
admin on Mon Mar 31 18:05:43 GMT 2025 , Edited by admin on Mon Mar 31 18:05:43 GMT 2025
|
PRIMARY | |||
|
C142929
Created by
admin on Mon Mar 31 18:05:43 GMT 2025 , Edited by admin on Mon Mar 31 18:05:43 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|